At ESGO 2026, the first results of an early clinical trial of a new drug called TUB-040<\/strong> in patients with platinum-resistant ovarian cancer<\/strong> were examined. This is an antibody-drug conjugate (ADC)<\/strong> – a targeted therapy that specifically recognizes cancer cells and transports a powerful cytotoxin directly to them. <\/p>\n TUB-040 is an ADC that targets a protein called NaPi2b<\/strong> (sodium-dependent phosphate transport protein 2B). NaPi2b is a transporter that regulates phosphate in tissues such as the lung and intestine and is more abundant at the cell surface in high-grade serous ovarian cancer and non-small cell lung cancer. <\/p>\n The NAPISTAR 1-01 study<\/strong> is an early Phase 1\/2a study<\/strong> that is primarily testing<\/p>\n how well a new medication is tolerated and<\/p>\n<\/li>\n which dosage is suitable.<\/p>\n<\/li>\n<\/ul>\n A total of 67 patients<\/strong> with platinum-resistant high-grade serous ovarian cancer were treated. Many of them had already received several therapies, on average four previous treatments<\/strong>, often including bevacizumab or PARP inhibitors. <\/p>\n The results are very promising for an early study:<\/p>\n A confirmed tumor reduction was found in 50% of the patients<\/strong>.<\/p>\n<\/li>\n Overall, the disease was at least stabilized<\/strong> in 96% of patients<\/strong>.<\/p>\n<\/li>\n<\/ul>\n In addition, many of the observed treatment responses were still ongoing at the time of the evaluation, so the final results are still pending.<\/p>\n The treatment was generally well tolerated<\/strong>. The most common side effects included nausea, fatigue and <\/span>changes in blood values. <\/span>Severe side effects were relatively rare. It is also important to note that no serious problems such as pneumonia, nerve damage or eye problems<\/strong> were observed. <\/p>\n The results show that TUB-040 could be a potential new treatment option<\/strong> for patients with platinum-resistant ovarian cancer, especially for those who have already failed multiple treatments.<\/p>\n However, this is still an early phase 1\/2 study<\/strong>. The drug therefore still needs to be investigated in larger studies<\/strong> before a decision can be made as to whether it will be used regularly in the future. <\/p>\nWhat was the study about?<\/h3>\n
\n
What results were observed?<\/h3>\n
\n
Side effects<\/h3>\n
What does this mean for patients?<\/h3>\n